Trial Profile

A Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2025 According to Disc Medicine media release, data from the study expected in H2 2025.
10 Jan 2025 According to Disc Medicine media release, the company announced that the multiple-dose data is expected H2 2025
08 Nov 2024 According to Disc Medicine media release, the company has obtained a $200 million non-dilutive term loan facility from Hercules Capital, which will support this multiple dose study in anemia of non-dialysis dependent chronic kidney disease (NDD-CKD), along with other studies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com